Артива Biotherapeutics CMO продал $5,148 в акции
Субхасис Банерджи, генеральный медицинский офицер Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), недавно отчитался о транзакциях, связанных с акциями компании. 18 августа 2026 года, мистер Банерджи продал 429 акций Artiva Biotherapeutics общей доли за общую стоимость $5,148. Акции были проданы по цене $12.0 за акцию. Акции currently trading at $11.70, reflecting remarkable 332% gain over past year from its 52-week low of $2.22.
prior to sale, Mister Banerjee acquired 429 акций общей доли через реализацию утильных stock options. These акции were acquired at price $1.92 per акцию, totaling $823. These transactions were conducted under a Rule 10b5-1 trading plan, which Mister Banerjee adopted on May 14, 2026.
Artiva Biotherapeutics’ efforts in rheumatoid arthritis treatment gain momentum
In other recent news, Artiva Biotherapeutics made significant strides in its rheumatoid arthritis treatment efforts. The company received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its AlloNK therapy in combination with rituximab, aimed at treating refractory rheumatoid arthritis. This designation allows Artiva to benefit from expedited development and review processes with the FDA. Additionally, Artiva presented encouraging clinical data at the European Alliance of Associations for Rheumatology Congress, where 71% of patients in a Phase 2a trial achieved an ACR50 response, indicating significant disease improvement.
Cantor Fitzgerald reiterated an Overweight rating on Artiva’s stock, maintaining a price target of $40.00. The firm discussed Artiva’s safety profile, strategy, and manufacturing capabilities in a recent webinar with the company’s CEO. These developments highlight Artiva’s ongoing efforts and progress in the field of rheumatologic disease therapies.
